Patients with breast cancer in chemotherapy with epirubicin (90 mg/m2) and cyclophosphamide (600 mg/m2) also showed reduced CAT, SOD, GSH, and GPx activity and increased TBARS levels [54]. This evidence concerns the gene CAT and breast carcinoma.